(UroToday.com) Following the presentation by Dr. Karim Fizazi on the phase 3 PEACE-1 trial. Dr. Axel Heidenreich provides a discussion presentation on important considerations for interpretation of this trial. The PEACE-1 phase 3 trial studied abiraterone acetate plus prednisone added to androgen deprivation therapy and docetaxel in men with de novo metastatic castration-sensitive prostate cancer (mCSPC).